baber/WOPTO huggingface dataset:
Patent JP-2002508009-A (JP)
Title: ラクトフェリンおよび関連分子を用いた感染性因子を不活化する方法および組成物
IPC: A61K39/145
Filed: 1999-04-12
Abstract: (57)【要約】
蛋白質を除去または分解するのに十分な条件下で、感染性因子を、実質的に純粋で低温殺菌されていない天然ラクトフェリンと接触させることによって感染性因子の表面蛋白質を除去または分解することにより、感染性因子を殺さずにその病原性を実質的に低下させる方法を開示する。
Patent JP-2001508812-A (JP)
IPC: A23L33/00
Filed: 1999-03-17
Abstract: Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.
Patent MX-149421-A (MX)
Inventor: NOLA FRANK JOSEPH
IPC: G05F1/70
Filed: 1981-02-13
Abstract: A power consumption reducing control circuit for a three phase induction motor (10), wherein power factors (P1, P2, P3) for the three phases (A, B, C) are separately determined and summed to provide a composite control signal, which is suitably conditioned (64, 66) and then employed to control the duty cycle of each phase of input power to the motor (10) through the appropriately timed gating of thyristors or Triacs (12, 14, 16).
Patent NZ-193822-A (NZ)
Title: Purification of aqueous solutions of iso-alpha-acids by precipitation of beta-acids
Inventor: BAKER C
IPC: C12C3/00
Filed: 1980-05-23
Abstract: A method of purifying aqueous solutions of iso- alpha -acids by removing  beta -acids therefrom comprises first bringing the solution to an iso- alpha -acid concentration of 0.5% to 10% w/w, particularly 0.5% to 5% w/w, then reducing the pH to a value in the range 7 to 10, preferably 8 to 9, so as to form an easily filtered precipitate of beta -acids. Preferably pH reduction is effected by bubbling carbon dioxide through the solution. The separated iso- alpha -acid solution may be concentrated to an extent that a phase separation takes place into two aqueous phases one of which has a higher iso- alpha -acid concentration than the other. The recovered iso- alpha -acid solution is suitable for direct addition to beer without haze formation.
Patent NZ-195214-A (NZ)
Title: Modem:phase of nyquist derived timing signal adjusted to correspond to phase of threshold crossing derived timing signal during training period
Inventor: GALPIN R K P
IPC: H04L25/03
Filed: 1980-10-09
Abstract: The submission makes use of the fact that where an adaptive equaliser (APS) is incorporated in a modem, some sort of training sequence is employed prior to the transmission of the data message. This training sequence usually incorporates a block of pseudo-random data (DIS) transmitted at the basic symbol rate to provide the equaliser (APS) with a relatively less distorted signal to operate on. During the training period both threshold-derived timing (TCTRL) and Nyquist-derived timing (NTRL) are produced. The Nyquist-derived timing (NTRL) is then phase-shifted (APS) to correspond to the threshold derived timing (TCTRL) which is valid during the training period. The phase shift (APS) is then fixed so that, when multi-level coding is introduced valid timing can still be obtained from the Nyquist-derived timing signal (NTRL). In addition in the event of transmission interruptions the invention allows timing recovery without the need for a new training cycle.
Patent NZ-206678-A (NZ)
Title: Stannic n-phosphonomethylglycine compounds and herbicidal compositions
Inventor: PRISBYLLA M P
IPC: C07F9/38
Filed: 1983-12-21
Abstract: Compounds having a ratio stannic (IV) cation to N-Phosphonomethylglycine anion of from about 1:1 to about 1:6, in particular tris-N-phosphonomethylglycine and tetra-N-phosphonomethylglycine and compositions containing them as useful as herbicides.
Patent NZ-212193-A (NZ)
Title: Dealkylation of 14-hydroxy-morphinan alkaloids; intermediates therefor
Inventor: HOFF C
IPC: C07D489/00
Filed: 1985-05-24
Abstract: 1. A process for the dealkylation of 14-hydroxymorphinan alkaloids, characterized in that it consists in : 1) reacting the 14-hydroxy derivative of the formula :  see diagramm : EP0164290,P5,F6  in which R' is CH3 or COCH3 , with excess ethyl chloroformate, in the presence of potassium carbonate and in a solvent, 2) subjecting the resulting carbamate of the formula :  see diagramm : EP0164290,P5,F2  in which R' is CH3 or COCH3 , to hydrolysis in a strong acid medium to give the corresponding dealkylated derivative of the formula :  see diagramm : EP0164290,P5,F3  in which R is CH3 or hydrogen.
Patent NZ-231371-A (NZ)
Title: Substituted 2-aminodecalin derivatives and plant fungicidal compositions
Inventor: ZIPPLIES MATTHIAS
IPC: C07C217/58
Filed: 1989-11-13
Abstract: 2-Aminodecalin derivatives of the formula I   <IMAGE> I  where R1, R2 and R3 are H or methyl, A is H, OH, O-alkylcarbonyl, O-benzoyl or O-CH3, R4 is H, cyclopropyl, alkyl, alkenyl, or alkynyl, R5 is alkyl, alkenyl or alkynyl which is substituted or unsubstituted, cycloalkyl or cycloalkenyl whic is substituted or unsubstituted, substituted phenylalkyl, substituted cycloalkyl-alkyl, substituted 5-membered heterocyclic ring, bicycloalkyl-alkyl or R4 and R5, together with the nitrogen atom, are a substituted or unsubstituted, saturated or unsaturated piperidine radical, their plant-tolerated salts and N-oxides, and fungicides containing these compounds.
Patent NZ-235031-A (NZ)
Title: Separation of cholesterol from food using co 2
Inventor: CULLY JAN
IPC: A23L5/20
Filed: 1990-08-23
Abstract: The present invention provides a process for the removal of cholesterol and/or cholesterol esters from foodstuffs by extraction with compressed carbon dioxide, wherein a) the cholesterol-containing extraction material is treated with compressed carbon dioxide at a pressure above 100 bar and at a temperature of from 10 DEG  to 90 DEG C., b) from the carbon dioxide stream loaded with cholesterol and/or cholesterol esters, as well as with further lipophilic components, the cholesterol components are selectively removed by adsorption on a solid adsorption agent or by adduct formation and c) at least a part of the carbon dioxide current substantially free from cholesterol components is again passed over the treated extraction material and/or used for the extraction of untreated, cholesterol-containing extraction material.
Patent NZ-236407-A (NZ)
Title: 3-amino chroman and thiochroman derivatives and medicaments
Inventor: LARSSON LARS-GUNNAR
IPC: C07D409/04
Filed: 1990-12-10
Abstract: Compounds of formula (I), processes for their preparation, pharmaceutical preparations, use of and method of treatment of disorders in CNS by using compounds of formula (I).
Patent NZ-243436-A (NZ)
Title: 4a-phenyl-6,7-heterocyclyl fused isoquinoline derivatives; preparatory processes and pharmaceutical compositions
Inventor: COLLE ROBERTO
IPC: C07D495/04
Filed: 1992-07-03
Abstract: PCT No. PCT/EP92/01483 Sec. 371 Date Jan. 5, 1994 Sec. 102(e) Date Jan. 5, 1994 PCT Filed Jul. 1, 1992 PCT Pub. No. WO93/01186 PCT Pub. Date Jan. 21, 1993.     <IMAGE>  (I)    Compounds of formula (I) in which, R is linear or branched alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, aralkyl or furan-2-yl alkyl; R1 and R2, which may be the same or different, are each hydrogen, hydroxy, alkoxy, or halogen; R3 is hydrogen, hydroxy or alkoxy; "Het" is optionally substituted single or fused heteroxyclic ring, containing from 5 to 10 ring atoms and comprising up to four heteratoms in the or each ring, selected from oxygen, nitrogen and sulphur; R4 and R5, which may be the same or different, are each hydrogen alkyl, halogen, nitro; CF, cyano, alkoxy carbonyl, NH, alkylcarbonylamino, hydroxy, alkoxy, or benzyl, are selective delta receptor agonists and are useful in the treatment of pain.
Patent NZ-244051-A (NZ)
Title: N-(2-naphthylethyl)urea and thiourea derivatives; preparatory processes and pharmaceutical compositions
Inventor: LESIEUR DANIEL
IPC: A61P25/28
Filed: 1992-08-21
Abstract: Compounds of formula (I): <IMAGE> for which the values of R, R1, R2 and X are defined in the description, which can be used as medicaments.
Patent NZ-273660-A (NZ)
Title: Optical fibre assembly of splice trays linked through manifold to optical device
Inventor: LLEWELLYN LAURENCE
IPC: G02B6/44
Filed: 1994-09-28
Abstract: PCT No. PCT/GB94/02111 Sec. 371 Date Mar. 28, 1996 Sec. 102(e) Date Mar. 28, 1996 PCT Filed Sep. 28, 1994 PCT Pub. No. WO95/09374 PCT Pub. Date Apr. 6, 1995An assembly 10 for use in connecting optical fibers to an optical fiber device having input and output tails comprises a plurality of housings 12 for housing optical fiber connections. Each housing 12 is typically mounted to, and supported by a respective routeing member 14. The routeing members are rigidly connected one to another such that the housings are arranged in an aligned bank. Each housing is pivotable for providing access thereto from the stowed position out of alignment with the other housings.
Patent NZ-304426-A (NZ)
Title: Process for preparing a fertiliser from organic waste material by adding nitrogen dioxide or a precursor
Inventor: FJELLDAL ERLING
IPC: C05F9/00
Filed: 1996-04-18
Abstract: PCT No. PCT/IB96/00346 Sec. 371 Date Dec. 31, 1997 Sec. 102(e) Date Dec. 31, 1997 PCT Filed Apr. 18, 1996 PCT Pub. No. WO96/33961 PCT Pub. Date Oct. 31, 1996A process for producing a fertilizer from an organic waste material is described which comprises treating a waste, having a water content of no more than 90% by weight and which has been alkalinized, with nitrogen dioxide or a precursor thereof in sufficient amount to reduce the pH by at least 2.0 pH units. The process produces an organic fertilizer in which the percentage by weight of nitrogen in the form of oxides of nitrogen is higher than percentage by weight of nitrogen in the form of ammonium ion.
Patent NZ-307505-A (NZ)
Title: Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
Inventor: SCHNORRENBERG GERD
IPC: C07D211/58
Filed: 1996-04-11
Abstract: Arylglycinamide derivatives of general formula (I) and pharmaceutically acceptable salts thereof, the symbols having the following meanings: R1 and R2 together with the nitrogen atom to which they are bound form a ring of formula (II) as shown, in which p is 2 or 3 and X stands for oxygen, N(CH2)nR6 or CR7R8; R3 denotes H, (C1-4)alkyl, unsubstituted or mono- to tri-substituted phenyl; R4 denotes phenyl (C1-4)alkyl or naphthyl(C1-4)alkyl, wherein phenyl may be substituted by 1 to 3 substituents; R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, CH2COOH, -CH2C(o)NH2, -OH or phenyl(C1-4)alkyl R6 is (C3-7)cycloalkyl, phenyl or naphthyl, wherein the phenyl may be mono- to tri-substituted; R7 and R8 represent H if R3 is unsubstituted or substituted phenyl or, R7 is phenyl, phenyl substituted by 1 to 3 substituents wherein the substituents independently of one another denote halogen (F, Cl, Br, I), (C1-4)alkyl, 0-(C1-4)alkyl, CF3 or OCF3, piperidinyl, 1-methylpiperidinyl or as further disclosed in the specification. Also disclosed is the use of the above compound in the treatment and prevention of Neurokinin-mediated disease.
Patent NZ-330749-A (NZ)
Title: Clostridium perfringens beta toxin derivatives and use in vaccines for clostridium perfringens infections
Inventor: SEGERS RUUD PHILIP ANTOON MARI
IPC: C07K14/33
Filed: 1998-06-19
Abstract: The present invention relates to detoxified immunogenic derivatives of Clostridium perfringens  beta -toxin or an immunogenic fragment thereof that have as a characteristic that they carry a mutation in the  beta -toxin amino acid sequence, not found in the wild-type beta -toxin amino acid sequence. The invention also relates to genes encoding such  beta -toxins, as well as to expression systems expressing such  beta -toxins. Moreover, the invention relates to bacterial expression systems expressing a native  beta -toxin. Finally, the invention relates to vaccines based upon detoxified immunogenic derivatives of Clostridium perfringens  beta -toxin, and methods for the preparation of such vaccines.
Patent NZ-332968-A (NZ)
Title: A controllably dissolvable silica-xerogel prepared via sol-gel
Inventor: AHOLA MANJA
IPC: A61K9/06
Filed: 1997-05-29
Abstract: The specification describes a controllably dissolvable silica-xerogel prepared via a sol-gel process.  The gel can be used as a vehicle for delivering biological agents, particulrly toremifene, more effectively.
Patent NZ-505074-A (NZ)
Title: Windlass with locking lever and controller to modulate amount of friction between gypsy and mounting shaft
Inventor: HENLY NICHOLAS CHARLES
IPC: B66D1/74
Filed: 2000-06-09
Abstract: Gypsy 103 is mounted on shaft 104. Locking lever 114 pivots about protrusions 117 and has tooth 120 which can engage pocket 112 in gypsy lock 111. By increasing the downward pressure applied to plunger 132 friction between protrusion 125 and groove 113 is increased.
Patent NZ-507898-A (NZ)
Title: Support for belly or abdominal region for pregnant women with the strap coming from the back to front and under the abdominal region
Inventor: WAKEFIELD WENDY MAY
IPC: A41D1/21
Filed: 2000-11-01
Abstract: An abdominal support (2) not incorporated in a garment wherein the support includes a pair of shoulder (3,4) and back straps (5,6). Each of the straps is designed to pass over one of the wearer's shoulders, cross over the wearer's upper back, and connect to the other shoulder and back straps at the wearer's side. A sling support secured to each shoulder and back strap at or adjacent to the wearer's side and a supporting sling arranged to extend from one sling support to the other, passing beneath the wearer's abdomen in use. The sling further incorporates length adjustment means.
Patent NZ-509250-A (NZ)
Title: Plastic pallet assembly having a top deck with columns projecting downwards that correspond and mate with columns projecting upwards from a bottom deck
Inventor: APPS WILLIAM P
IPC: B65D19/00
Filed: 1999-06-25
Abstract: A pallet assembly includes a top deck formed of plastic which has a first opposing surface having a plurality of first flanged portions projecting downwardly therefrom. The pallet assembly the top deck has a substantially planar upper surface upon which a plurality of objects are capable of resting. The pallet assembly also includes a bottom deck which is also formed of plastic and has a second opposing surface with a plurality of second flanged portions projecting therefrom in an upward direction. The plurality of second flanged portions correspond to and securely mate with the plurality of flanged portions to define a plurality of columns between the top deck and bottom decks, said columns having box beam cross-section for providing strength to the pallet assembly. The top deck includes a top member and a mid-top member, and the bottom deck includes a bottom member and a mid-bottom member
Patent NZ-513320-A (NZ)
Title: Treatment of chronic viral infections with M. vaccae
Inventor: STANFORD JOHN LAWSON
IPC: A61K35/74
Filed: 2000-02-16
Abstract: The use of a Mycobacterium vaccae (M. vaccae) preparation, said preparation being substantially free of non- vaccae antigenic material, for the manufacture of a medicament for use n the treatment of a chronic viral infection such as an HPV infection, a herpes simplex virus, a subacute sclerosing pan-encephalitis or a hepatitis virus infection, excluding an HIV infection.
Patent NZ-514353-A (NZ)
Title: Combination preparation for treating malaria
Inventor: CHULAY JEFFREY DAVID
IPC: A61K31/122
Filed: 2000-04-05
Abstract: The use of atovaquone and/or a combination of atovaquone, proguanil and primaquine, in the manufacture of a medicament for treating malaria, particularly P. vivax malaria, in mammals, including humans.
Patent NZ-514923-A (NZ)
Title: Use of an acid preparation as feed additive in farm animal husbandry
Inventor: RACZEK NICO N
IPC: A23K50/60
Filed: 2001-10-18
Abstract: A solid preparation comprises sorbic acid, at least one acid which is liquid at room temperature (23oC) and at least one other organic acid different from sorbic acid which is solid at room temperature. Preferably the liquid acid is chosen from propionic, acetic, lactic, valeric, formic, isobutyric, trimethylacetic, 2-methyl-butyric, hexanoic, butyric, phosphoric, hydrochloric or sulfuric acids and the solid organic acids is chosen from fumaric, tartaric acid, malic, succinic, adipic, ascorbic, gluconic, citric and amino acids. Also described is a feed which comprises the preparation and the use of the preparation as an animal feed additive.
Patent NZ-519895-A (NZ)
Title: Method and apparatus for earth anchoring
Inventor: CONDON BRENDAN ROBERT
IPC: E01F9/011
Filed: 2000-12-08
Abstract: An earth anchoring member (30) having an upper body portion and a lower ground engaging portion having opposed side faces, a flattened insert end (31) with a leading edge, a raised portion extending from each said face, each raised portion tapering towards and terminating at the insert end and two opposed ground retaining flanges (33, 35) which extend outwardly from the upper body portion and terminate at the leading edge.
Patent NZ-521543-A (NZ)
Title: Piperidine derivative compounds for treatment of a chemokine or H1 mediated disease
Inventor: LAWRENCE LOUISE
IPC: A61K31/496
Filed: 2001-04-05
Abstract: A piperidine derivative compound of a formula (I), a process for preparing this compound; and its use in the treatment of a chemokine (such as CCR3) or H1 mediated disease state is disclosed, wherein the variables are as defined in the specification.
Patent NZ-522506-A (NZ)
Title: Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1, pharmaceutical use and preparation process thereof
Inventor: BARF TJEERD
IPC: C07D277/38
Filed: 2001-05-22
Abstract: A compound of the formula (II) wherein: T is an aryl ring or heteroaryl ring or aryl-C2-alkenyl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono-or di-substituted, amide which is optionally mono-or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C-acyl, C1-6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono-or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4- (2-ethoxy-2-oxoethyl)-1, 3-thiazol-2-yl] amino} carbonyl); with the proviso that when R1 is H, X is CH2, Y is CO, R2 is EtO and B is H, then T is not 2,4-dichloro-5-methylphenyl, 4-chlorophenyl, 4-chloro-2,5-dimethylphenyl, 2, 4 difluorophenyl, 3-nitrophenyl and phenyl; R1 is hydrogen or C1-6-alkyl; X is CH2 or CO; Y is CH2, CO or a single bond; B is hydrogen, C1-6-alkyl; R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4morpholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-1, 3,4-oxadiazol-2-yl; NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl, or C1-6-alkyl substituted with one or more aryl or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1 dioxidothiomorpholine, 2-(3, 4-dihydro-2(1H) isoquinolinyl), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by C1-6-alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl; OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6 alkyl or form together morpholinyl; R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6- acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof. The compounds of formula (II) inhibit the human 11-b-hydroxysteroid dehydrogenase type 1 enzyme (11-b-HSD1), and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
Patent NZ-530578-A (NZ)
Title: A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5 -dioxo-oxazolidine intermediate compounds
Inventor: CID PAU
IPC: C07K5/062
Filed: 2002-07-23
Abstract: Disclosed is a process for the preparation of a compound of formula (IV) (perindopril) or an ester or a salt thereof comprising: reacting a compound of formula (I) (wherein Ra, Rb and Rc represent alkyl as defined in the specification) with a compound of the formula X2C=O (wherein each X independently represents a leaving group) to give a compound of formula (II); and Reacting compounds of formula (II) with compounds of formula (III) (wherein Rd represents H or a protecting group). Also disclosed are compounds of formula (II).
Patent NZ-537732-A (NZ)
Title: Improved multilayer video screen
Inventor: ENGEL GABRIEL DAMON
Filed: 2003-07-15
Abstract: A display device comprises at least two display layers (7, 9) which overlap at least in part. At least one of the display layers has a dissimilar configuration to the other display layer such that moiré interference is reduced. The dissimilar configuration can be tessellated pixel patterns optionally with dissimilar sub-pixel patterns.
Patent NZ-541487-A (NZ)
Title: Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
Inventor: MULLER GEORGE W
IPC: A61K6/00
Filed: 2003-12-29
Abstract: Disclosed is a compound having the formula (I) wherein; Y is -C(O)-, -CH2, -CH2C(O)-, -C(O)CH2-, or SO2; Z is -H, -C(O)R3-, -(C0-1-alkyl)-SO2-(C1-4-alkyl), -C1-8-alkyl, -CH2OH, CH2(O)(C1-8-alkyl) or CN; R1 and R2 are each independently -CHF2, -C1-8-alkyl, -C3-18-cycloalkyl, or -(C1-10-alkyl)(C3-18-cycloalkyl), and at least one of R1 and R2 is CHF2 ; and the rest of the substituents are disclosed within the specification. Also disclosed is the use of the above compound or a therapeutically acceptable salt, solvate, hydrate, or stereoisomer thereof for the manufacture of a medicament for inhibiting PDE4 in a mammal or for modulating the production of TNF-alpha in a mammal or for inhibiting a matrix metalloproteinase (MMP) in a mammal.
Patent NZ-541643-A (NZ)
Title: Imidazol-4-yl-ethynyl-pyridine derivatives
Inventor: BUETTELMANN BERND
IPC: C07D/
Filed: 2004-03-05
Abstract: Disclosed is a compound which is a compound which is a 4-[1-aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivative or a 4-[1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivative or a pharmaceutically acceptable salt thereof. The compounds may have the formula (I), wherein the substituents are as defined in the specification. The compounds are metabotropic glutamate receptor 5 (mGluR5) antagonists useful in the treatment of neurological disorders including anxiety.
Patent NZ-543862-A (NZ)
Title: Method of joining separable components and container closure system formed by the same
Inventor: ADAMS BRIAN
IPC: B65D/
Filed: 2004-05-26
Abstract: A tamper-evidencing closure for a container having a container opening is disclosed. The closure comprises a closure base 34 having a dispensing aperture adapted for mounting on the container adjacent to the container opening. A sealing member 35 closes the aperture and the container opening. A connection member 36 releasably interconnects the closure base and the sealing member. The closure base and the sealing member are formed of a first material, and the connection member is formed of a second material that is more pliable than the first material.